We are live on ! Find out more
OC

Oarsman Capital Portfolio holdings

AUM $806M
1-Year Est. Return 19.96%
This Fund
S&P 500
This Quarter Est. Return
+5.53%
1 Year Est. Return
+19.96%
3 Year Est. Return
+61.37%
5 Year Est. Return
+74.92%
10 Year Est. Return
+242.94%
AUM
$237M
AUM Growth
+$17.9M
Cap. Flow
+$7.26M
Cap. Flow %
3.07%
Top 10 Hldgs %
21.82%
Holding
191
New
8
Increased
79
Reduced
68
Closed
3

Sector Composition

Rank Sector Weight
1 Financials 10.56%
2 Consumer Discretionary 10.49%
3 Healthcare 10.29%
4 Industrials 10.23%
5 Technology 9.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IVW icon
176
iShares S&P 500 Growth ETF
IVW
$72.5B
$202K 0.09%
+5,636
New +$199K
NVG icon
177
Nuveen AMT-Free Municipal Credit Income Fund
NVG
$2.65B
$174K 0.07%
11,285
FRED
178
DELISTED
Fred's Inc
FRED
$85K 0.04%
+13,200
New +$86.5K
PIM
179
Franklin Master Intermediate Income Trust
PIM
$149M
$56K 0.02%
11,882
CCL icon
180
Carnival Corporation Ltd
CCL
$36.1B
-16,870
Closed -$1.11M
GM icon
181
General Motors
GM
$74.7B
-37,480
Closed -$1.31M
DD
182
DELISTED
Du Pont De Nemours E I
DD
-5,775
Closed -$466K

Similar funds

Oarsman Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Oarsman Capital held 191 positions worth $237M, up 8.2% from $219M the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Oarsman Capital deployed $7.26M of net new capital in Q3 2017, opening 8 new positions and adding to 79 existing holdings. Its largest new stake was ProShares Short S&P500: 13,900 shares worth $1.79M.

By sector, the portfolio is most concentrated in Financials at 11% of assets, down from 11% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $970K trimmed.

  • Oarsman Capital's largest Q3 2017 buy was ProShares Short S&P500: 13,900 shares worth $1.79M.
  • Oarsman Capital added most to DuPont de Nemours in Q3 2017, an estimated $2.44M increase.
  • Oarsman Capital's biggest Q3 2017 reduction was Teva Pharmaceuticals, cutting an estimated $970K.
  • Oarsman Capital fully exited General Motors in Q3 2017, selling an estimated $1.31M.
  • Oarsman Capital's ten largest holdings make up 22% of its $237M portfolio in Q3 2017.
  • Oarsman Capital opened 8 new positions and closed 3 in Q3 2017.
  • Oarsman Capital's portfolio value rose 8.2% quarter-over-quarter to $237M.

Based on Oarsman Capital's 13F filing for Q3 2017, filed 13 Nov 2017.